Catalenas solutions for the opioid painkiller OxyContin are in high demand, as are anti-inflammatory drugs like Celebrex.
The company recently raised $11.6 million in a Series B round led by Accel Partners and others.
The firm has been aggressively building out its products, announcing an initial round of $2.5 billion in February and plans to raise another $1 billion this year.
That $1.6 billion will go toward developing new drugs and developing its global network of distribution centers.
Catalent is not the only pharma company that’s expanding its offerings to address the opioid crisis.
Pfizer has been ramping up its own prescription-painkillers, and Valeant Pharmaceuticals has developed an opioid pain reliever called OxyContin.
In both cases, the companies have built out their supply chains to provide higher-quality and lower-cost options.
But Catalens plans to go beyond its existing drugs, launching its own brand of painkiller, which is currently under development.
Catalyst’s strategy focuses on three primary areas: pain management, prevention and quality-of-life.
The drugs will help reduce the frequency of opioid-related deaths, and help prevent or reverse chronic pain.
Catalista and the company say the drug is less addictive and has fewer side effects than existing medications.
It’s also more affordable, as Catalista is currently $200 a pill, versus the average $1,000 cost of a prescription opioid.
It will have the potential to provide pain relief for millions of people who are struggling to get by.
But Catalistas goal is to develop its own drug.
The drug will not be directly marketed to patients.
It is also likely to be sold over the counter and to private insurers.
Catalia and its partners have also built a network of distributors and other distributors to help sell Catalistan to patients and other pharmaceutical companies.
It says that a third of the drug will be available to the general public within the next few years.